Search Technologies

Adoptive cell therapy (ACT) using tumor-specific T cells leads to complete tumor regression in some cancer patients. However, limiting the efficacy of this therapy is that T cells become functionally exhausted and have short half-lives after adoptive transfer. Researchers at the National Cancer Institute (NCI) have discovered a novel method to generate long-lived memory tumor-specific T cells with enhanced tumor clearance and persistence upon in vivo transfer. NCI is seeking parties interested in licensing and/or co-developing potassium hydroxy citrate to promote longevity and efficacy of tumor-specific T cells.

The National Cancer Institute seeks partners interested in licensing or collaborative research to co-develop a treatment for Ewing's Sarcoma, with a goal of preclinical evaluation leading to clinical testing.

The National Cancer Institute Cancer Genetics Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize mouse epithelial cancer cell lines.

The National Cancer Institute (NCI) seeks licensees for an automated digital pathology device which integrates tissue sectioning, staining, and image acquisition. The device is compatible with high-throughput data analyses.

This technology represents a safe yet highly efficient strategy for somatic cell reprogramming, and has broad applicability for basic research and disease modeling.

The National Cancer Institute (NCI) seeks research a co-development partner and/or licensees for applications utilizing the nanoparticle platform technology for delivery of cancer-specific microRNAs, particularly for therapeutic uses in surface cancers, such as mesothelioma.

The National Cancer Institute (NCI) seeks research and co-development partners and/or licensees for human monoclonal antibodies and antibody-based therapeutics targeting the B-cell antigen CD22

The National Cancer Institute seek parties interested in in-licensing and/or collaborative research to develop and commercialize cell labeling, cell tracking, cell trafficking, cell-based therapy, and PET imaging for cancer.

The technology is directed to the use of single-stranded RNA overhangs or toeholds of varying lengths (< 12 nucleotides) contained in nucleic acid-based nanoparticles which trigger the association of these nanoparticles and activates multiple functionalities such as gene silencing and/or cell-specific targeting. The use of RNA toeholds is superior to that of DNA toeholds in that it allows for smaller nanoparticles (fewer nucleotides for the toeholds) resulting in greater chemical stability, less immunogenic and higher yield of production. The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for use of RNA overhangs or toeholds in nucleic acid nanoparticles.